Christoph Kapitza

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 14

Top Topics

Glycemic Control

Placebo Controlled

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schoelch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist BI 456906. Diabetes, obesity & metabolism (2022)
Juris J Meier, Daniel Robert Quast, Michael A Nauck, Nina Schenker, Carolyn F Deacon, Jens J Holst, Leona Plum-Mörschel, Christoph Kapitza
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, obesity & metabolism 24 (5) (2022)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism (2022)
Juris J Meier, Charlotte Granhall, Ulrike Hoevelmann, Andrea Navarria, Leona Plum-Moerschel, Chethana Ramesh, Andrea Tannapfel, Christoph Kapitza
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes, obesity & metabolism 24 (4) (2022)
Daniel Robert Quast, Michael A Nauck, Nina Schenker, Björn A Menge, Christoph Kapitza, Juris J Meier
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes, obesity & metabolism 23 (10) (2021)
Jennifer Leohr, Christof Kazda, Rong Liu, Shobha Reddy, Mary Anne Dellva, Mark Matzopoulos, Mei Teng Loh, Thomas Hardy, Oliver Klein, Christoph Kapitza
Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study. Diabetes, obesity & metabolism (2021)
Tim Heise, Helle Linnebjerg, David Coutant, Elizabeth LaBell, Eric Zijlstra, Christoph Kapitza, Juliana M Bue-Valleskey, Qianyi Zhang, Mary Anne Dellva, Jennifer Leohr
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, obesity & metabolism 22 (10) (2020)
Christoph Kapitza, Leszek Nosek, Wolfgang Schmider, Lenore Teichert, Bhaswati Mukherjee, Irene Nowotny
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes. Diabetes, obesity & metabolism 23 (3) (2020)
Juris J Meier, Björn A Menge, Nina Schenker, Silke Erdmann, Melanie Kahle-Stephan, Freimut Schliess, Christoph Kapitza, Michael A Nauck
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (4) (2019)
Juris J Meier, Nina Schenker, Melanie Kahle, Freimut Schliess, Christoph Kapitza, Björn A Menge
Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study. Diabetes, obesity & metabolism 19 (11) (2017)
Christoph Kapitza, Irene Nowotny, Anne Lehmann, Karin Bergmann, Baerbel Rotthaeuser, Leszek Nosek, Reinhard H A Becker
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes, obesity & metabolism 19 (5) (2017)